Search Results

7 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 25

    Misperception of e-cigarette harm growing among American adults, 2013-2015

    VERRON T.(1); GUO M.(1); VARIGNON B.(1); O'CONNELL G.(2); WALELE T.(2); CAHOURS X.(1)
    (1) SEITA - Imperial Brands plc, Paris, France; (2) Fontem Ventures B.V., Amsterdam, The Netherlands
    Electronic cigarettes (e cigarettes) have been characterised as significantly less harmful than smoked tobacco by an increasing number of public health authorities. However, the proportion of American adults who perceive e cigarettes to be equally or more ...
  2. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 60

    Assessing changes in biomarkers of effect in smokers who switch to a closed system electronic cigarette

    MASON L.; CAHOURS X.; O'CONNELL G.; WALELE T.
    Imperial Brands, Bristol, U.K.
    Previous studies have demonstrated that when smokers switch to an electronic cigarette, they are exposed to significantly lower levels of carcinogens and toxicants. As a result, there is a reported significant reduction in biomarkers of exposure to levels ...
  3. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 39

    The use of high content screening (HCS) in human primary lung cells to assess e-liquids of differing flavors and nicotine concentrations

    SIMMS L.(1); CZEKALA L.(1); STEVENSON M.(1); PHILLIPS G.(1); WALELE T.(2)
    (1) Imperial Brands, Bristol, U.K.; (2) Fontem Ventures, Amsterdam, The Netherlands
    Due to the current scientific debate and evolving regulatory landscape, new assays are needed to quickly determine the subtle biological response of e-liquids for both stewardship and product development purposes. For stewardship, all ingredients in the e ...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 52

    Biological test procedure for fresh generated cigarette smoke and e-cigarette aerosols under air-liquid interface (ALI) exposure in 24 and 96 multi-well plates

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    Cigarette smoke and e cigarette aerosol contain particulate matter/liquid droplets in the solid phase as well as volatile substances in the gas phase. Both fractions are of potential toxicological relevance and should be considered when assessing ...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 53

    Use of human derived cell lines to increase the biological relevance of cigarette condensate, non-tobacco materials and e-liquids testing

    WIECZOREK R.(1); TRELLES STICKEN E.(1); WALELE T.(2); CZEKALA L.(3); SIMMS L.(3)
    (1) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (2) Fontem Ventures, Amsterdam, The Netherlands; (3) Imperial Tobacco Limited, Bristol, U.K.
    The in vitro testing strategy of tobacco products is mainly based on the testing of extracts from cigarette smoke condensates. An accepted industry wide assay battery has been developed over recent years which delivers reliable results for the ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping with ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, STPOST 21

    The use of in vitro human biomarkers from relevant primary cell lines, to assess the effects of increasing nicotine concentration in e-liquids

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); BERG E.(2); WALELE T.(3)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) DiscoverX Corporation, Fremont, CA, U.S.A.; (3) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    As part of the ongoing stewardship of electronic cigarettes, and in line with the National Academies of Sciences “ Toxicity Testing in the 21st Century: A Vision and a Strategy ”, Fontem Ventures B.V. have investigated the utility of a series of endpoints ...